A consensus statement on lipid management after acute coronary syndrome. Issue 6 (1st September 2018)

• Record Type: Journal Article
• Authors: Schiele, François; Farnier, Michel; Krempf, Michel; Bruckert, Eric; Ferrières, Jean; Angoulvant, Denis; Boccara, Franck; Bonnet, Jacques; Bonnet, Jean-Louis; Bruckert, Eric; Cayla, Guillaume; Chatot, Marion; Chopard, Romain; Collet, Jean-Philippe; Danchin, Nicolas; Ducrocq, Gregory; Elbaz, Meyer; Ferrari, Emile; Galinier, Michel; Farnier, Michel; Ferrières, Jean; Gerbaud, Edouard; Guedj, Dominique; Kownator, Serge; Krempf, Michel; Lemesle, Gilles; Levai, Laszlo; Mansencal, Nicolas; Mansourati, Jacques; Meune, Christophe; Morel, Olivier; Paillard, François; Piot, Christophe; Probst, Vincent; Puymirat, Etienne; Roubille, François; Sabouret, Pierre; Schiele, François; Teiger, Emmanuel;
• Is Part Of: European heart journal. Volume 7:Issue 6(2018)
• Page Start: 532
• Page End: 543
• Publication Date: 2018-09-01
• Subjects: Acute coronary syndrome -- statins -- ezetimibe -- lipid-lowering therapy -- familial hypercholesterolaemia -- LDL cholesterol; 616.1205
• DOI: 10.1177/2048872616679791
• Languages: English
• ISSNs: 2048-8726

Abstract

Abstract: In patients admitted for acute coronary syndrome (ACS), the guidelines of the European Society of Cardiology give a Class I, Level A recommendation for the prescription of high-intensity statins to be initiated as early as possible, regardless of the low-density lipoprotein cholesterol (LDL-C) level. Although statins are widely prescribed after ACS, the intensity of therapy and the proportion of patients achieving target LDL-C values are often not in line with recommendations due to a lack of compliance with guidelines by the physicians, a lack of compliance with treatment or poor tolerance by patients, and poor dose adaptation. In this context, a group of French physicians came together to define strategies to facilitate and improve the management of lipid-lowering therapy after ACS. This paper outlines the scientific rationale for the use of statins at the acute phase of ACS, the utility of ezetimibe, the measurement of LDL-C during the course of ACS, the opportunities for detecting familial hypercholesterolaemia and the results of the consensus for the management of lipid-lowering therapy, illustrated in two decision-making algorithms.